FDA Category 1 List: Impact on Australian Compounding

What Is the FDA Category 1 List?

The US Food and Drug Administration (FDA) maintains a list of bulk drug substances evaluated for use in compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Substances placed on the Category 1 list are those the FDA has determined should not be used in compounding due to safety concerns, lack of clinical evidence, or other regulatory factors.

This is a US-specific regulatory action - but its effects ripple across the global peptide supply chain, including into Australia.

Which Peptides Are Affected?

Several peptides popular in the Australian market have been placed on or nominated for the FDA Category 1 list. Key substances include:

1. BPC-157 (Body Protection Compound-157) - One of the most widely prescribed peptides in Australian clinics
2. Thymosin Beta-4 (TB-500) - Used for tissue repair and recovery
3. AOD-9604 - A growth hormone fragment used for metabolic support
4. Selank and Semax - Nootropic peptides with a smaller but dedicated user base
5. Dihexa - A cognitive enhancement peptide with limited clinical data

Ongoing Nominations

The FDA continues to evaluate additional peptides for potential Category 1 placement. Australian practitioners and pharmacies should monitor the FDA's Pharmacy Compounding Advisory Committee (PCAC) updates for new nominations.

How This Affects Australian Supply

Australia does not directly follow FDA compounding rules. However, the practical impact is significant because of supply chain dependencies:

API Sourcing Disruption

1. Many Australian compounding pharmacies source active pharmaceutical ingredients (APIs) from US-based manufacturers or distributors
2. When the FDA restricts a substance from compounding, US manufacturers often reduce or cease production of that API
3. This creates a global shortage that affects Australian pharmacies even though Australian law still permits compounding these substances

Alternative Sourcing Challenges

1. Pharmacies must identify new API suppliers outside the US supply chain
2. These suppliers must meet TGA and pharmacopoeia quality standards
3. Qualification of new suppliers takes time - typically 3 to 12 months
4. During the transition, some peptides may be temporarily unavailable

Price Implications

1. Reduced competition among API suppliers typically drives prices upward
2. Australian consumers may see cost increases of 15 to 40 percent for affected peptides
3. Smaller compounding pharmacies may be disproportionately affected due to lower purchasing power

The Australian Regulatory Position

The TGA has maintained an independent stance on peptide scheduling:

1. Substances on the FDA Category 1 list are not automatically restricted in Australia
2. The TGA conducts its own risk-benefit assessments under the Poisons Standard framework
3. However, the TGA has acknowledged it monitors international regulatory actions as part of its ongoing review process
4. Future TGA decisions may be influenced by the evidence base compiled during FDA evaluations

What Practitioners Should Do

1. Check supply availability with your compounding pharmacy before prescribing affected peptides
2. Identify alternative therapeutic options where supply disruptions are likely
3. Stay informed about both FDA and TGA regulatory updates
4. Communicate transparently with patients about potential availability changes

The Peptide Register tracks the regulatory status of peptides across both Australian and international frameworks to help practitioners stay current.